Artificial intelligence ‘fingerprinting’ fights hard-to-detect cancers


Difficult-to-detect cancers like glioblastoma have single-digit survival rates, but to treat them early requires sophisticated techniques to detect, treat and monitor them.Early detection is critical for these conditions, which is why Reveal Surgical is working to change that with its new AI-based Sentry technology, which uses a combination of ARTIFICIAL intelligence and Raman spectroscopy to provide real-time tissue diagnosis for otherwise invisible tumors.Raman spectroscopy uses laser light scattering to detect the molecular structure and composition of materials.In this case, the material is human tissue.Reveal Surgical uses Raman spectroscopy, an optical, non-invasive imaging technology, to generate unique “fingerprints” for different types of tumors, allowing doctors to fingerprint tissue samples, explained Chris Kent, CEO of Reveal Surgical.They were compared with recorded tumors using Reveal software.Reveal designed a cancer “fingerprint” detector using Raman spectroscopy and built a fingerprint database in the ARTIFICIAL intelligence system.This will provide doctors with real-time molecular data on tumors encountered during the examination.Reveal said they collected thousands of fingerprints from hundreds of patients and many different tissues.Reveal then used those fingerprints to build a predictive AI classifier — which, of course, became more accurate over time as the system collected and processed more and more fingerprints.Now, when surgeons examine suspicious tissue, the ‘fingerprints’ they detect will be checked against a fingerprint database.Ai is able to sift through more than 14,000 measurements from five different cancer types and tell you if something is cancer.The classifier can identify hard-to-find cancer tissue in real time, which could allow surgeons to remove more cancer tissue during surgery.For now, Reveal is focusing on identifying brain cancers that are extremely difficult to detect (due to the invasive and complex nature of brain surgery and imaging) and dangerous (like the aforementioned glioblastoma).But the company says the technology is unknown, and it’s exploring applications for Sentry in prostate cancer, lung cancer, and gynecology. The Reveal website also mentions possible applications for breast tissue analysis.Sentry’s job is to help lead the next wave of data-driven surgery.The beauty of ARTIFICIAL intelligence is that it is effective collaboration.It continuously collects data and benefits from the experience of every surgeon who uses it.For now, however, the Sentry tool is for inspection only.

Leave a Reply

Your email address will not be published.